Completed Clinical Trials

Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma

By April 24, 2017 No Comments


Malignant Mesothelioma

Estimated Enrollment: 82

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: EORTC-08052|JJPRD-26866138CAN2012|2006-000009-51

Study First Received: April 9, 2007

Last Updated: April 19, 2013

Estimated Primary Completion Date: April 2010


Primary Outcome Measures:

Progression-free survival (PFS) rate at 18 weeks|Overall objective response rate|Symptomatic response rate|Safety as measured by NCI CTCAE v3.0 and the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity questionnaire|Duration of PFS|Overall survival

Sponsors and Collaborators:

European Organisation for Research and Treatment of Cancer – EORTC

Website Link:

Leave a Reply

Call Now